statement
UBS believes the key to next year's consumption recovery is not a sudden burst of demand but whether prices can recover, with hog prices an important driver.
A statement by 瑞銀. Statements are as reported by the cited publishers — not verified by DecisionGateway.
瑞銀認為,明年消費復甦的關鍵不在需求突然爆發,而是價格能否回升。其中,豬價將是重要推手。
Discussion
Related claims
UBS expects the Chinese government is unlikely to launch a large-scale consumption stimulus plan, and future policy will focus more on areas such as birth subsidies, unemployment protection and pensions.瑞銀 · predictionAs supply decreases, hog prices are expected to rebound in the first quarter of 2027, potentially lifting CPI by 0.2 to 0.4 percentage points; if other factors are unchanged, next year's CPI may even exceed market expectations and top 1%.彭燕燕 · predictionLooking ahead to 2027, as hog capacity continues to be reduced and hog prices are expected to rebound, driving CPI higher, companies may successively cut promotions and raise prices in the first and second quarters of next year, and China's consumer market may see a "reflation" rally.彭燕燕 · predictionOctober data are positive, but it is too early to speak of a sustained recovery in consumer demand; the improvement in sentiment partly coincided with lower gasoline prices, while purchasing power remains under pressure.capitalizator_ua · statementChina's consumer market should not expect a rapid demand recovery at present, but after six years of correction, valuations of both staple and discretionary consumer goods are at relatively low levels.彭燕燕 · statementFurther purchases will be restrained by a reduction in the pig herd, which weakens demand for soybean meal.post author · prediction
More claims by 瑞銀
Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.predictionTigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.statementIf the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.predictionFrontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.statementAfter the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.statement
All claims by 瑞銀